BioNTech halted its Phase 2 trial for a colorectal cancer vaccine after a Data Safety Monitoring Board found no efficacy, causing its stock to fall 8%. This setback also pressured Moderna's shares, which dropped 6%, despite its recent melanoma vaccine success. Pfizer's stock remained mostly unaffected due to its diversified portfolio and recent FDA approval for a COVID-19 vaccine update. The failure highlights challenges for mRNA vaccines in treating immunotherapy-resistant tumors and prompts investors to reassess the potential of mRNA cancer therapies. Upcoming trial results and industry data may clarify the future outlook for these treatments.
Moderna's shares surged 9% after its Phase 3 melanoma study was selected for a prestigious Presidential Symposium slot at the European Society for Medical Oncology congress. This high-profile placement signals strong confidence in the study's potenti...
Moderna's stock surged 6% to $154, extending a 137% gain over the past month driven by promising Phase 2b melanoma vaccine data presented at ASCO 2026. The data showed a 49% reduction in risk of recurrence or death when combining Moderna's intismeran...
